Onasemnogene Abeparvovec-xioi Gene-Replacement Therapy for Spinal Muscular Atrophy Type 1 (SMA1): Phase 3 US Study (STR1VE) Update (1828)
Year: 2020
Type: article
Source: Neurology
Authors: John W. Day, Claudia A. Chiriboga, Thomas O. Crawford, Basil T. Darras, Richard S. Finkel, Anne M. Connolly, Susan T. Iannaccone, Nancy L. Kuntz, Loren D.M. Peña, Perry B. Shieh, Edward C. Smith, Meredith Schultz, Douglas E. Feltner, Sitra Tauscher-Wisniewski, Francis G. Ogrinc, Ankita Shah, Haojun Ouyang, Thomas Macek, Elaine Kernbauer, Douglas M. Sproule, Jerry R. Mendell
Institutions: Stanford Medicine, Columbia University Irving Medical Center, Johns Hopkins Medicine, Johns Hopkins Hospital, Boston Children's Hospital, Nemours Children's Health System, Nationwide Children's Hospital, The Ohio State University, The University of Texas Southwestern Medical Center, Lurie Children's Hospital, Cincinnati Children's Hospital Medical Center, University of California, Los Angeles, Duke University, Duke Medical Center
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3049486141